Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Hypertension in 2011

New insights—from risk factors to treatment implications

The results of several hypertension studies published in 2011 have contributed to our knowledge on the risks of and treatment for this condition, including the effects of slow-wave sleep, nocturnal dosing of medication, variability in post-stroke blood-pressure reduction, and the impacts of a low-sodium diet.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Hermida, R. C., Ayala, D. E., Mojon, A. & Fernandez, J. R. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J. Am. Soc. Nephrol. 10.1681/ASN.2011040361.

  2. Minutolo, R. et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am. J. Kidney Dis. 50, 908–917 (2007).

    Article  PubMed  Google Scholar 

  3. Rahman, M. & Appel, L. J. Should reducing nocturnal blood pressure be a therapeutic target in CKD? The time is ripe for a clinical outcomes trial. Am. J. Kidney Dis. 50, 901–903 (2007).

    Article  PubMed  Google Scholar 

  4. Black, H. R. et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289, 2073–2082 (2003).

    Article  CAS  PubMed  Google Scholar 

  5. Fung, M. M. et al. Decreased slow wave sleep increases risk of developing hypertension in elderly men. Hypertension 58, 596–603 (2011).

    Article  CAS  PubMed  Google Scholar 

  6. Sandset, E. C. et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 377, 741–750 (2011).

    Article  CAS  PubMed  Google Scholar 

  7. Aiyagari, V. & Gorelick, P. B. Management of blood pressure for acute and recurrent stroke. Stroke 40, 2251–2256 (2009).

    Article  PubMed  Google Scholar 

  8. Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L. & Ebrahim, S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am. J. Hypertens. 24, 843–853 (2011).

    Article  CAS  PubMed  Google Scholar 

  9. Bibbins-Domingo, K. et al. Projected effect of dietary salt reductions on future cardiovascular disease. N. Engl. J. Med. 362, 590–599 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Esler, M. D. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 376, 1903–1909 (2010).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Ethics declarations

Competing interests

G. L. Bakris has received grants/research support from Forest laboratories, Medtronic, Novartis, and Relypsa. He has acted as a consultant for Abbott, CVRx, Eli Lilly, FDA, Johnson & Johnson, Novartis, Servier, and Takeda.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bakris, G. New insights—from risk factors to treatment implications. Nat Rev Cardiol 9, 75–77 (2012).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing